Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;17(1):31-47.
doi: 10.1007/s40291-013-0020-0.

Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions

April D Sorrell  1 , Carin R Espenschied, Julie O Culver, Jeffrey N Weitzel
Affiliations
Review

Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions

April D Sorrell et al. Mol Diagn Ther. 2013 Feb.

Abstract

Prevalent as an acquired abnormality in cancer, the role of tumor protein p53 (TP53) as a germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is often dramatic and affects the full life course, with a propensity to develop rare tumors in childhood and multiple common cancers of unexpectedly early onset in adulthood. In this article, we review the clinical relevance of germline mutations in the TP53 tumor suppressor gene to current healthcare practice, including the optimal ways to identify patients with Li-Fraumeni syndrome (LFS), to recognize the core cancers associated with LFS, and to develop strategies for early detection of LFS-associated tumors. Several TP53-targeted approaches to improve outcomes in LFS patients are also reviewed. A case report is used to highlight special TP53 testing dilemmas and unique challenges associated with genetic testing decisions in the current age of rapidly advancing genomic technologies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A graphic representation of the TP53 gene (boxes) and protein (cylinders), adapted from the IARC TP53 database.[21] The TP53 gene contains 11 exons represented by the numbered boxes. The exons 2-4 (yellow) encode for the two Transactivation domains (I, II) of the protein (amino acids 1 through 42 and 43-62). Exons 5-8 (blue) encode for the DNA binding portion of the protein (amino acids 102-292). Exons 9 and 10 (green) encode for the Oligomerisation (amino acids 323-356) and Regulatory (amino acids 363-393) domains. The approximate location of the initiation codon (ATG) is denoted.
Fig. 2
Fig. 2
Summary of the most frequent TP53 germline mutations by codon, reproduced from the International Agency for research on Cancer (IARC) TP53 database.[21] Each vertical line represents the codon location of a TP53 germline mutation. The codon location for the most frequently reported mutations (based on percentage of base substitutions) are located at the top of the vertical line. For instance, the Brazilian founder mutation, at codon position 337, is the most frequently reported mutation.
Fig. 3
Fig. 3
Pedigree for the family described in the case example
See this image and copyright information in PMC

References

    1. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li–Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250–6. - PubMed
    1. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer. 1997;76(1):1–14. - PMC - PubMed
    1. Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51(2):344–56. - PMC - PubMed
    1. Upton B, Chu Q, Li BD. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms. Surgical oncology clinics of North America. 2009;18(1):145–56. ix. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. - PubMed

Publication types

Substances